Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)

Phase 2

Terminated

• Conditions: Hepatitis B, Chronic
• Interventions: Drug: EYP001a; Drug: Placebo; Drug: Nucleotide analogue (Entecavir or Tenofovir Disoproxil)

• Registration Number: NCT04465916
• Lead Sponsor: Enyo Pharma

Brief Summary

This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional cure rates.

Detailed Description

A total of 49 eligible patients will be enrolled and randomized at approximately 14 study sites. Patients will be randomized prior to study drug (EYP001a or placebo and NA) administration on Day 1 in the ratio of 3:1 into 2 arms:

* Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)

* Control Arm: Placebo + NA daily (12 patients)

The maximum total engagement duration for eligible patients in this study is up to 370 days: 90 days screening, 112 days (16 weeks) treatment period and 168 days (24 weeks) follow-up.

Patients enrolled in the study will be assessed as outpatients. Patient screening will occur no more than 90 days prior to the Day 1 visit. Eligible patients will undergo further assessments on Day 1 to qualify for study drug administration on Day 1.

The visits during the study are planned as below:

* Screening visit: 12 weeks (90 days)

* 16 weeks treatment period:

* Treatment Visit 1 (Week 1 \[Day 1\])

* Treatment Visit 2 (Week 2 \[Day 14 ±3 days\])

* Treatment Visit 3 (Week 4 \[Day 28 ±3 days\])

* Treatment Visit 4 (Week 6 \[Day 42 ±3 days\])

* Treatment Visit 5 (Week 8 \[Day 56 ±3 days\])

* Treatment Visit 6 (Week 10 \[Day 70 ± 3 days\])

* Treatment Visit 7 (Week 12 \[Day 84 ± 3 days\])

* Treatment Visit 8 (Week 14 \[Day 98 ± 3 days\])

* Treatment Visit 9 (Week 16 \[Day 112±3 days\])

* 24 weeks safety follow-up period:

* Follow-up Visit 1 (Week 20 \[Day 140 ±7 days\])

* Follow-up Visit 2 (Week 28 \[Day 196 ±7 days\])

* Follow-up Visit 3 (Week 40 \[Day 280 ±7 days\]) Note: during follow-up patients are kept on NA until the end of the trial: Week 40 (consolidation Phase).

Study Timeline

• Study Start: 2020-05-12
• Study First Submitted: 2020-07-06
• Study First Submitted QC: 2020-07-09
• Study First Posted: 2020-07-10
• Primary Completion: 2021-06-17
• Study Completion: 2021-11-25
• Results First Submitted: 2022-08-22
• Results First Submitted QC: 2022-09-21
• Status Verified: 2022-10
• Last Update Submitted: 2022-10-11
• Results First Posted: 2022-10-12
• Last Update Posted: 2022-11-02

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

• Are on stable NA therapy at least 12 months from the screening date (ETV or TDF)
• Has virally suppressed CHB:

HBV DNA <LLOQ and serum HBsAg >100 IU/mL

• Has liver imaging to screen for hepatocellular carcinoma or concomitant pancreaticobiliary disease either in the prior 6 months or at screening.
• Is not of childbearing potential or, if of childbearing potential, is not pregnant as confirmed by a negative serum human chorionic gonadotropin test at screening and is not planning a pregnancy during the course of the study.

Main

Read More

Exclusion Criteria

• Is an employee of a contract research organization (CRO), vendor, or Sponsor involved with this study.

• Has known hepatocellular carcinoma or pancreaticobiliary disease.

• Neutropenia (defined by two confirmed values within screening period of <1500/μL).

• Has Gilbert syndrome.

• Shows evidence of worsening liver function, defined as either a confirmed (two assessments at least 3 days apart) increase >2 ULN ALT or AST or an increase of >1.5 × first assessed value of TBL or associated with clinical signs or symptoms of liver impairment.

• Has known or suspected non-CHB liver disease

• History of cirrhosis or liver decompensation, including ascites, hepatic encephalopathy, or presence of oesophageal varices.

• Probable or possible F3 stage with a vibration controlled transient elastography (VCTE). Patients with normal baseline ALT and VCTE >8.8 kPa are excluded. Patients with baseline ALT >ULN (but <2ULN per EC5) and who have VCTE >10.5 kPa at baseline are excluded 11.

• Has known history of alcohol abuse or daily heavy alcohol consumption

• Has clinically relevant immunosuppression, including, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.

• Has used anti-HBV medications other than NAs within 90 days prior to screening.

• Has any of the following exclusionary laboratory results at screening:

  1. Estimated glomerular filtration rate <60 mL/min/1.73 m2 (the Modification of Diet in Renal Disease formula).
  2. Thyroid-stimulating hormone >1.5× ULN or abnormal free triiodothyronine or free thyroxine.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental Arm	EYP001a	Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
Experimental Arm	Nucleotide analogue (Entecavir or Tenofovir Disoproxil)	Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)
Control Arm	Placebo	Control Arm: Placebo + NA daily (12 patients)
Control Arm	Nucleotide analogue (Entecavir or Tenofovir Disoproxil)	Control Arm: Placebo + NA daily (12 patients)

Primary Outcome Measures

Name	Time	Method
HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment	LS mean at week 16 (Day 1, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12, Week 14, and Week 16)	Efficacy of Vonafexor on top of NA assessed as HBsAg decline (Δ log10) from Day 1 to Week 16 of treatment

Secondary Outcome Measures

Name	Time	Method
Virologic Failure Rate	40 weeks	Virologic failure rate (breakthrough)2 of HBV-DNA (% patients with a confirmed quantifiable HBV DNA increase of ≥ 1log10 HBV DNA copies/mL above LLOQ3) assessed at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period

Trial Locations

Locations (18)

ENYO PHARMA Investigative site PL01; 🇵🇱 Białystok, Poland

ENYO PHARMA Investigative site PL02; 🇵🇱 Lublin, Poland

ENYO PHARMA Investigative site PL03; 🇵🇱 Warszawa, Poland

ENYO PHARMA Investigative site PL04; 🇵🇱 Zawiercie, Poland

ENYO PHARMA Investigative site AU03; 🇦🇺 Melbourne, Australia

ENYO PHARMA Investigative site KR07; 🇰🇷 Pusan, Korea, Republic of

ENYO PHARMA Investigative site KR05; 🇰🇷 Seongnam, Korea, Republic of

ENYO PHARMA Investigative site KR02; 🇰🇷 Seoul, Korea, Republic of

ENYO PHARMA Investigative site PL05; 🇵🇱 Łódź, Poland

ENYO PHARMA Investigative site AU02; 🇦🇺 Brisbane, Australia

ENYO PHARMA Investigative site AU01; 🇦🇺 Melbourne, Australia

ENYO PHARMA Investigative site AU04; 🇦🇺 Melbourne, Australia

ENYO PHARMA Investigative site KR04; 🇰🇷 Pusan, Korea, Republic of

ENYO PHARMA Investigative site KR01; 🇰🇷 Seoul, Korea, Republic of

ENYO PHARMA Investigative site KR06; 🇰🇷 Séoul, Korea, Republic of

ENYO PHARMA Investigative site PL06; 🇵🇱 Kielce, Poland

ENYO PHARMA Investigative site KR03; 🇰🇷 Seoul, Korea, Republic of

ENYO PHARMA Investigative site HK01; 🇭🇰 Hong Kong, Hong Kong